Our Publications
Find below a list of our peer-reviewed published manuscripts since 2017.
2023
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072-y. Online ahead of print.
Jentzsch M, Bischof L, Brauer D, Backhaus D, Ussmann J, Franke G-N, Vucinic V, Platzbecker U, Schwind S. Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation. Cancers 2023, 15(4), 1312.
Backhaus D, Brauer D, Pointner R, Bischof L, Vucinic V, Franke GN, Niederwieser D, Platzbecker U, Jentzsch M, Schwind S. A high Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) does not impair Outcomes after Non-Myeloablative Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients 60 Years or older. Bone Marrow Transplant. 2023; 58(1):30-38.
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke GN, Herling M, Platzbecker U, Schwind S. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022; 12(12):170.
2022
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke GN, Herling M, Platzbecker U, Schwind S. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022; 12(12):170.
Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. Blood Adv. 2022; 6(15):4570-4580.
Herrmann L, Bischof L, Backhaus D, Brauer D, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M. Outcome prediction by the knowledge bank approach in AML patients undergoing allogeneic stem cell transplantation. Am J Hematol 2022. 97(10):E382-E384.
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LK, Backhaus D, Brauer D, Goldmann K, Franke GN, Vucinic V, Niederwieser D, Mims AS, Platzbecker U, Eisfeld AK, Schwind S. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv 2023 Feb 14;7(3):436-444.
2021
Grimm J, Jentzsch M, Bill M, Backhaus D, Brauer D, Küpper J, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Biological and Clinical Implications of SRSF2 Mutations in Transplanted Acute Myeloid Leukemia Patients. Am J Hematol. 2021 Oct 1; 96(10):1287-1294.
Jentzsch M, Grimm J, Bill M, Küpper J, Backhaus D, Brauer D, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Measurable Residual Disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation. Bone Marrow Transplant. 2021 Oct;56(10):2610-2612.
Schwind S, Jentzsch M, Kubasch AS, Metzeler KH, Platzbecker U. Myelodysplastic Syndromes: Biological and Therapeutic Consequences of the Evolving Molecular Aberrations Landscape. Neoplasia. 2021 Sept 30; 23,1101–1109.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Clinical Value of the Measurable Residual Disease Status within the ELN Risk Groups in AML Patients undergoing Allogeneic Stem Cell Transplantation. Am J Hematol. 2021 Jul 1;96(7): E237-E239.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, Goldmann K, Niederwieser D, Platzbecker U, Schwind S. Clinical relevance of morphologic remission and MRD status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer Journal. 2021 Apr 29; 11:80.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant. 2021 Apr;56(4):936-945.
Brauer D, Backhaus D, Pointner R, Vucinic V, Niederwieser D, Platzbecker U, Schwind S*, Jentzsch M*. Nutritional status at diagnosis and pre-transplant weight loss impact outcomes of acute myeloid leukemia patients following allogeneic stem cell transplantation. Hemasphere. 2021 Feb 10; 5(3): e532.
2020
Jentzsch M, Bill M, Grimm J, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. Ann Hematol. 2020. 99(10):2417-2427.
Jentzsch M, Bill M, Grimm J, Schulz J, Schuhmann L, Brauer D, Goldmann K, Wilke F, Franke GN, Behre G, Pönisch W, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. Haematologica. 2020 Oct 1;105(10):229260.
Grimm J, Jentzsch M, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Prognostic Impact of the ELN 2017 Risk Classification in AML Patients Receiving Allogeneic Transplantation. Blood Adv. 2020. Aug 25;4(16):3864–3874.
Jentzsch M, Grimm J, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Outcomes of older patients with NPM1 mutated and FLT3-ITD negative acute myeloid leukemia receiving allogeneic transplantation. Hemasphere. 2020 Jan 3;4(1):e326.
Schwind S, Jentzsch M, Bach E, Stasik S, Thiede C, Platzbecker U. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Curr Treat Options Oncol. 2020;21(1):8.
2019
Jentzsch M, Döhring C, Linke R, Hille A, Grimm J, Pönisch W, Vucinic V, Franke GN, Behre G, Niederwieser D, Schwind S. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Am J Hematol. 2019 Dec;94(12):1344-52.
Jentzsch M, Schwind S, Bach E, Stasik S, Thiede C, Platzbecker U. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers (Basel). 2019 Oct 23;11(11).
Jentzsch M, Geus U, Grimm J, Vucinic V, Pönisch W, Franke GN, Behre G, Niederwieser D, Schwind S. The pre-treatment CD34+/CD38- cell burden as prognostic factor in MDS patients receiving allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1560-6.
Grimm J, Bill M, Jentzsch M, Beinicke S, Häntschel J, Goldmann K, Schulz J, Cross M, Franke GN, Behre G, Vucinic V, Pönisch W, Lange T, Niederwieser D, Schwind S. Clinical Impact of Clonal Hematopoiesis in Acute Myeloid Leukemia Patients Receiving Allogeneic Transplantation. Bone Marrow Transplant. 2019 Aug;54(8):1189-97.
2018
Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J, Beinicke S, Häntschel J, Cross M, Vucinic V, Pönisch W, Behre G, Franke GN, Lange T, Niederwieser D, Schwind S. Digital droplet PCR based absolute quantification of pre-transplant NPM1mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol. 2018 Oct;97(10):1757-65.
Schmalbrock LK, Bonifacio L, Bill M, Jentzsch M, Goldmann K, Grimm J, Cross M, Lange T, Pönisch W, Behre G, Vucinic V, Franke GN, Niederwieser D, Schwind S. Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 May;53(5):640-3.
2017
Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S, Häntschel J, Pönisch W, Franke G-N, Vucinic V, Behre G, Lange T, Niederwieser D, Schwind S. High Blood BAALC Copy Numbers at Allogeneic Transplantation Predict Early Relapse in Patients with Acute Myeloid Leukemia. Oncotarget. 2017 Sep 27;8(50):87944-54.
Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, Pönisch W, Franke GN, Niederwieser D, Schwind S. Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplant. 2017 Jun;52(6):932-5.
Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pleß M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, BehreG, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Prognostic Impact of the CD34+/CD38- Cell Burden in Patients with Acute Myeloid Leukemia receiving Allogeneic Stem Cell Transplantation. Am J Hematol. 2017 Apr;92(4):388-96.
Collaborations: Pönisch Lab
Wang SY, Holzhey T, Heyn S, Zehrfeld T, Fricke S, Hoffmann FA, Becker C, Braunert L, Edelmann T, Paulenz I, Hitzschke M, Flade F, Schwarzer A, Fenchel K, Franke GN, Vucinic V, Jentzsch M, Schwind S, Hell S, Backhaus D, Lange T, Niederwieser D, Scholz M, Platzbecker U, Pönisch W. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study. J Cancer Res Clin Oncol. 2023 Jul;149(7):3739-3752.
Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönefelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm M, Remane Y, Platzbecker U, Scholz M. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone and Bortezomib (BPV). J Cancer Res Clin Oncol. 2021;147(8): 2349-2359.
Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Pönisch W. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-53.
Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Pönisch W. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-58.
Pönisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, Al-Ali HK, Niederwieser D. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22.
Collaborations: Vucinic Lab
Teipel R, Rieprecht S, Trautmann-Grill K, Röllig C, Klötzer C, Zimmer K, Rathaj G, Bach E, Brückner M, Heyn S, Wang SY, Jentzsch M, Schwind S, Kretschmann T, Egger-Heidrich K, Remane Y, Franke GN, von Bonin M, Bornhäuser M, Platzbecker U, Hölig K, Merz M, Vucinic V. Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma. Transfusion. 2023 Oct 18. doi: 10.1111/trf.17566. Online ahead of print.
Georgi TW, Kurch L, Franke GN, Jentzsch M, Schwind S, Perez-Fernandez C, Petermann N, Merz M, Metzeler K, Borte G, Hoffmann S, Herling M, Denecke T, Kluge R, Sabri O, Platzbecker U, Vucinic V. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J Cancer Res Clin Oncol. 2023 Aug;149(9):6131-6138.
Franke GN, Pfannes R, Heyn S, Brückner M, Rieprecht S, Bach E, Remane Y, Pönisch W, Niederwieser D, Schwind S, Platzbecker U, Jentzsch M, Vucinic V. Analysis of Stem Cell Collections in Adult Patients with Ewing Sarcoma. Transfusion.2022; 62(8):1612-1618.
Hell S, Jentzsch M, Franke GN, Jäkel N, Schulze S, Edelmann J, Nenoff K, Grieb N, Jeremic V, Cross M, Leiblein S, Bach E, Pönisch W, Al-Ali HK, Schwind S, Platzbecker U, Lange T, Niederwieser D, Vucinic V. Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15. Bone Marrow Transplant. 2022 Feb 18. doi: 10.1038/s41409-022-01609-6. Online ahead of print.
Pflug N, Littauer A, Beverungen D, Sretenovic A, Wahnschaffe L, Braun T, Dechow A, Jungherz D, Otte M, Monecke A, Bach E, Franke GN, Schwind S, Jentzsch M, Platzbecker U, Herling M, Vucinic V. Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations. Front Oncol. 2022 Jan 5;11:775313.
Vucinic V, Jentzsch M, Leiblein S, Bach E, Remane Y, Forster KS, Cross M, Pönisch W, Schwind S, Franke G-N, Platzbecker U, Niederwieser D. Stem-cell Mobilization of Healthy Sibling Donors with Pegfilgrastim - A Prospective open-label Phase II trial (EudraCT No: 2005-004971-39. Transfusion. Transfusion. 2022 Jan;62(1):157-164.
Gerhardt K, Jentzsch M, Georgi T, Sretenovic A, Cross M, Bach E, Monecke A, Leiblein S, Hoffmann S, Todorovic M, Bila J, Sabri O, Schwind S, Franke GN, Platzbecker U, Vucinic V. Salvage Therapy with Polatuzumab-vedotine, Bendamustine and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients with Aggressive Lymhomas Relapsing After Therapy With Chimeric Antigen Receptor T-cells – Report on Two Cases. Front. Oncol., 2021 Sep 16;11:737645.
Ramdohr F, Monecke A, Jentzsch M, Zehrfeld T, Borte G, Schwind S, Franke GN, Metzeler KH, Platzbecker U, Vucinic V. Extramedullary Clonal Hematopoiesis with Indeterminate Potential. Clinical Lymphoma, Myeloma and Leukemia. 2021 Sep;21(9):e696-e698.
Vucinic V, Jentzsch M, Schwind S, Bach E, Leiblein S, Remane Y, Rieprecht S, Otto S, Kubasch A-S, Behre G, Cross M, Platzbecker U and Franke G-N. Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. Front. Oncol. 2020 Sep 16;10:1746.